Twentyeight-Seven Therapeutics
PrivateLast Round
Series A
Extension
May 10, 2019
Total Funding Raised
$82.75M
Company Overview
Redona Therapeutics is a biotechnology company that develops small molecule drugs targeting enzymes that regulate RNA and DNA processes to treat serious diseases like cancer and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Twentyeight-Seven Therapeutics Comparables
Compare Twentyeight-Seven Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| STORM Therapeutics | 82% | |
| Accent Therapeutics | 81% | |
| Expansion Therapeutics | 81% | |
Twentyeight-Seven Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | May 10, 2019 | ||||
| Series A | Sep 6, 2018 |
Key People
Founding team and executive leadership
Twentyeight-Seven Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM Capital | Series A |
| Vertex Ventures HC | Series A |
| MPM BioImpact | Series A |
| Osage University Partners | Series A Extension |
| Astellas Venture Management | Series A |
| Sofinnova Partners | Series A Extension |
| Longwood Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors grew 149% MoM, from 437 to 1.1K.
- May 10, 2019
$18M round led by Sofinnova Partners
Twentyeight-Seven Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Twentyeight-Seven Therapeutics's valuation, stock price, and market status.